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Abstract
Background: The expression of major histocompatibility complex class II (MHCII) antigens in
both mouse and human tumors is rare, and these antigens are not easily inducible by IFN-gamma
(IFNg). Since MHCII may play an important role in the development of host antitumor immune
response, we explored the possibility of restoring MHCII inducibility in several IFNg-resistant
tumor cell lines using protein kinase C (PKC) agonists phorbol myristate acetate (PMA) or
Bryostatin.
Results: Tumor cells were co-cultured with various concentrations of PMA and IFNg for 48 hr.
The expression of MHCII antigens and receptors IFNgR1 and IFNgR2 was determined by flow
cytometry. We showed that the presence of as little as 0.1 ng/ml of PMA in tissue culture restored
the ability of weakly inducible LS1034 colon carcinoma cells to express MHCII in response to IFNg
(100 – 10,000 IU/ml) in a dose-dependent manner. Likewise, Bryostatin 1, as low as 10 ng/ml
produced a 5–6 fold upregulation of MHCII. The effect of PMA was not observed in two other
poorly responding cell lines, MSTO-211H mesothelioma and HepG2 hepatocellular carcinoma, and
was abrogated by relatively high concentrations of PKC inhibitors staurosporine (100 nM) and GF
109203X (1,000 nM). Both surface and intracellular staining of all cell lines with antibodies against
IFNgR1 and IFNgR2 failed to detect any increase in IFNg receptor expression following incubation
with PMA.
Conclusion: In this study we showed that IFNg-inducibility of MHCII antigens in weakly inducible
LS1034 colorectal carcinoma cell line can be rescued by concomitant incubation with PKC agonists.
Bryostatin 1 may be considered for further investigation of IFNg-dependent MHCII induction in
resistant tumors in vivo.
Background
Major histocompatibility complex class II molecules
(MHCII) are heterodimeric transmembrane glycoproteins
that bind antigenic peptides and present such peptides to
CD4+ T cells. Although MHCII are not expressed by the
vast majority of studied mouse and human tumors, CD4+
T lymphocytes specific to MHCII-restricted tumor anti-
gens have been found in various cancers [1]. Those lym-
phocytes are believed to be generated in vivo following the
recognition of MHCII-tumor peptide complexes ex-
pressed by host antigen presenting cells and can cause re-
gression of MHCII-negative tumors indirectly, via
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secretion of cytokines such as IL-2 or IFNg [2]. The re-
leased cytokines can recruit and activate cytotoxic CD8+ T
lymphocytes and/or accessory cells (eosinophills, macro-
phages) which further mediate tumor destruction.
It has been recently appreciated that sufficient concentra-
tions of secreted IFNg may also induce susceptible tumors
to express the MHCII molecules, potentially leading to in-
creased direct contact with CD4+ T cells [3]. Even though
some reports indicate that tumor sensitivity to IFNg is not
required to elicit tumor regression [4], it is conceivable
that the IFNg-induced MHCII expression on tumor cells
may boost the effector phase of antitumor responses
through additional cytokine release or direct tumor eradi-
cation by CD4+ T cells. Indeed, the CD4+ T cells that di-
rectly destroy MHCII-positive tumors were identified [5].
In the clinic, the expression of MHCII on colorectal carci-
nomas is correlated with more favourable prognosis [6].
Adoptive transfer studies show that ex vivo activated CD4+
T cells are able to recognize, and to eliminate, MHCII-pos-
itive tumors either by themselves [7] or in co-operation
with CD8+ T cells [8]. It has been also demonstrated that
the increased MHCII expression on tumor cells and mac-
rophages following treatment with IFNg in vivo was asso-
ciated with enhanced efficacy of adoptive T cell therapy in
a mouse model of metastatic sarcoma [9].
Unfortunately, the induction of MHCII on tumor cells by
IFNg in vivo is difficult [10]. In fact, the reported inducible
tumors seem to be limited to freshly transplanted tumor
cells [9,11] or malignant cells present in the ascitic fluid
[12]. Many tumors do not express MHCII after treatment
with recombinant IFNg in vitro either [13].
Given the role that MHCII may play in tumor immunity,
further attempts to restore inducibility in IFNg-resistant
tumors appear to be warranted. In this regard, several sub-
stances have recently been tested using in vitro models of
noninducible tumor cell lines. It was reported that some
agents, e.g. histone deacetylase inhibitors [14] or DNA
methylation inhibitors [15], can rescue the IFNg induci-
bility of MHCII in cultured tumor cells.
In this study, we explored whether the effect can be
achieved by yet another category of modulators, the PKC
agonists, chosen because PKC has been shown to function
as an upstream regulator of the MAPK pathway [16] that
is involved in both IFNg signal transduction [17] and reg-
ulation of gene expression [18].
Specifically, the influence of a potent PKC activator, PMA,
and clinically tested drug, Bryostatin 1, on the IFNg-in-
duced MHCII expression in several IFNg-resistant tumor
cell lines was examined. Previously, PMA was shown to
augment IFNg-mediated MHCII expression in MHCII-in-
ducible tumor cell lines [19,20]. Here, we report that the
presence of PMA in tissue culture restores IFNg-dependent
MHCII expression in the poorly-responding LS1034 co-
lon carcinoma cell line but fails to produce this effect in
two other IFNg-resistant cell lines, MSTO-211H mesothe-
lioma and HepG2 hepatocellular carcinoma. We also
show that the IFNg-dependent MHCII expression in
LS1034 cell line can be rescued by clinically acceptable
concentrations of Bryostatin 1.
Results
Induction of MHCII molecules by IFNg in four different tu-
mor cell lines
We first compared the induction of MHCII molecules in
SW480, LS1034, MSTO-211H and HepG2 tumor cells in
response to different concentrations of IFNg. MHCII anti-
gens were initially undetectable in all cell lines tested. In-
cubation with as little as 102 IU/ml IFNg induced a 10-
fold increase of MHCII-specific fluorescence in SW480 co-
lon carcinoma cell line. In contrast, LS1034 demonstrated
only weak (1.4- to 1.6-fold) increases in level of MHCII,
and remained weakly inducible even when concentration
of IFNg was increased to 104 IU/ml (Figure 1). MSTO-
211H, mesothelioma, cell line also showed a weak induc-
tion of MHCII in response to IFNg and HepG2, hepatocel-
lular carcinoma, was completely non-inducible (data not
shown).
It should be noted, however, that we observed a small
population of LS1034 cells (about 5–10% of all cells) that
demonstrated a modest (3- to 4-fold) increase in MHCII-
specific fluorescence after incubation with 102–104 IU/ml
IFNg (data not shown). This could suggest that a small
subset of LS1034 cells might acquire an inducible pheno-
type at a certain stage of cell differentiation.
PMA rescues IFNg inducibility of MHCII in low responding 
LS1034 colon carcinoma cell line
We next attempted to restore IFNg inducibility of MHCII
in poorly responding tumor cell lines by adding PKC ago-
nist PMA into culture medium containing variable con-
centrations of IFNg. PMA did not improve IFNg
inducibility of MHCII in MSTO-211H and HepG2 cell
lines (data not shown). The LS1034 cells, on the other
hand, demonstrated a robust increase in MHCII
expression.
The magnitude of response of LS1034 cells varied greatly
from experiment to experiment depending not only on
concentration of IFNg, but also on concentration of PMA
and even on type of the PMA agent (DMSO or ethanol).
Therefore, the experiments were arranged in a factorial de-
sign for accurate analysis of possible interactive effects.
For each combination of treatments, a 3-letter alphanu-
meric code was assigned (Table 1). Four dose levels ofCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/4
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IFNg combined with 5 dose levels of PMA and 2 dose lev-
els of ethanol generated 40 groups and the design was rep-
licated 4 times.
The results demonstrated a substantial increase in MHCII
expression in LS1034 cell line following combined incu-
bation with PMA and IFNg (Figure 2). Two-factor analysis
of variance revealed that the magnitude of MHCII induc-
tion in LS1034 cells was almost totally determined by
concentration of IFNg (F2;36 = 29.3, P < 10-6). Higher re-
sponse to IFNg tended to be associated with higher con-
centration of PMA in some experiments, but the overall
effect of PMA did not reach a commonly accepted level of
significance (F3;36 = 1.9, P = 0.14). Interestingly, the effect
of PMA did reach significance in cultures supplemented
with 172 mM ethanol (F3;36 = 3.0, P = 0.043; groups
09b→12b, 15b→18b, 21b→24b). No interaction effect
between PMA and IFNg was found (F6;36 = 0.14, P = 0.99).
Since there were no 2-factor interactions, several single-
factor groups were added, and data were re-analysed by
using one-way ANOVA. Different combinations of PMA
and IFNg were compared to the highest dose of IFNg used
without PMA (group 20a or 20b). Multiple comparisons
were made using Tukey's HSD test and Scheffe's test (the
latter test is more conservative). Results demonstrate that
the expression level of MHCII reached a plateau at 103 IU/
ml IFNg in the presence of 102–104 ng/ml PMA and 172
Figure 1
MHCII expression induced by IFNg in two colon carcinoma cell lines. Cells were incubated with various concentra-
tions of IFNg for 48 hr. The difference in MHCII inducibility between the low responding LS1034 cell line (mean ± sd, n = 8 
independent experiments) and the high responding SW480 cell line (mean ± sd, n = 2) is at least 5-fold.
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mM ethanol. Further increases in concentration of IFNg
(to 104 IU/ml) did not result in statistically significant in-
creases of MHCII expression (Figure 2B).
Figure 2 also demonstrates that ethanol was totally inac-
tive alone (compare group 20a vs. 20b) but it significantly
improved the MHCII induction in the presence of PMA.
Because of variation between experiments, the effect of
EtOH could not be seen clearly in Figure 2. For that rea-
son, pair-wise comparisons were made between cell cul-
tures incubated either with PMA or with a combination of
PMA and EtOH. Specifically, group 09a was compared to
group 09b, etc. Data shown in Figure 3 confirm that EtOH
significantly improved PMA-potentiated response to IF-
Ng. Linear regression analysis also revealed that the effect
of ethanol was more pronounced at 102 IU/ml IFNg.
Taken together, the above results showed a strong poten-
tiating effect of PMA on IFNg-induced HLA-DR expression
in LS1034 cell line and no changes in two other poorly in-
ducible cell lines.
Expression levels of IFNg receptors in four different tumor 
cell lines do not change following incubation with PMA
It has been previously shown that potentiating effect of
phorbol esters on IFNg-dependent MHCII induction in
THP-1 monocytic cell line was associated with the in-
crease in synthesis of IFNg receptors [19]. For that reason,
we questioned whether PMA could produce similar
changes in LS1034 colon carcinoma cells. We compared
the expression of alpha and beta chains of IFNg receptor
(IFNgR1 and IFNgR2) in LS1034 carcinoma and three
other tumor cell lines before and after 48 hr incubation
with 103 ng/ml PMA and 172 mM ethanol. Results, plot-
ted in Figure 4, show that untreated and PMA-treated tu-
mor cells express about the same levels of IFNgR1 and
IFNgR2. Moreover, the level of IFNgR1 in HepG2 cells ac-
tually drops after exposure to PMA. Therefore, we con-
clude that it is unlikely that PMA action in LS1034
carcinoma is mediated through increased synthesis of
IFNg receptors.
Expression of the retinoblastoma protein is not lost in 
LS1034, MSTO-211H and HepG2 cell lines
A substantial percentage of human tumors lose the expres-
sion of the retinoblastoma tumor suppressor protein
(Rb), important as a necessary condition for IFNg-mediat-
ed induction of MHCII [21]. Therefore, we wished to de-
termine whether the poor IFNg inducibility of MHCII in
LS1034, MSTO-211H and HepG2 cell lines could be ex-
plained by the loss of Rb. Immunofluorescent staining
with a Rb-specific mAb (clone G3-245) demonstrated that
all cell lines tested expressed Rb (Figure 5).
A closer look at Figure 5 reveals that the 4 cell lines can be
ranked according to their Rb contents in the following
order: SW480 > LS1034 > MSTO-211H > HepG2. This
ranking would be valid only if fluorescence intensity cor-
relates closely with the absolute contents of Rb protein per
cell. However, this may not always be the case. For exam-
ple, the number of epitopes recognized by G3-245 mAb
may be reduced if tumor cells express viral oncoproteins
that bind and inactivate Rb [22].
It is important to note that certain mutations greatly re-
duce transport of newly synthesized Rb molecules into the
nucleus where Rb performs its function [23]. As the flow
cytometry protocol does not allow us to discriminate be-
Table 1: Experimental conditions for measuring IFNg-dependent induction of MHCII molecules in LS1034 colon carcinoma cells
col 1 col 2 col 3 col 4
PMA, ng/ml ethanol, mM DMSO, µl/ml 0 IU/ml 102 IU/ml 103 IU/ml 104 IU/ml
row 01 0 0 0 01a 07a 13a 19a
row 02 0 0 1 02a 08a 14a 20a
row 03 101 01 0 3 a 09a 15a 21a
row 04 102 01 0 4 a 10a 16a 22a
row 05 103 01 0 5 a 11a 17a 23a
row 06 104 01 0 6 a 12a 18a 24a
row 07 0 0 0 01b 07b 13b 19b
row 08 0 172 1 02b 08b 14b 20b
row 09 101 172 1 03b 09b 15b 21b
row 10 102 172 1 04b 10b 16b 22b
row 11 103 172 1 05b 11b 17b 23b
row 12 104 172 1 06b 12b 18b 24b
One-way ANOVA was performed on groups that are shown in italic font (08→12, 14→18, and 20→24). Two-factor ANOVA was performed on 
groups that are shown in bold font (09→12, 15→18 and 21→24).Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/4
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tween cytoplasmic and nuclear staining, the question
about the presence of functional Rb protein in the exam-
ined cell lines remains open.
Effect of protein kinase inhibitors on physiological and 
PMA-potentiated response to IFNg
The discovery of novel "non-kinase" phorbol ester recep-
tors challenges the use of phorbol esters as selective PKC
activators [24]. Therefore, we were interested in whether a
member of the PKC family mediated the effect of PMA in
LS1034 cells or whether some other proteins could also be
involved. Specifically, we investigated whether two inhib-
itors, staurosporine and GF 109203X, could abrogate
PMA-potentiated response of LS1034 cells to IFNg.
Staurosporine is a wide-spectrum kinase inhibitor and its
Figure 2
PMA rescues MHCII inducibility in low responding LS1034 colon carcinoma cell line. Expression levels of MHCII 
(mean ± sd) induced by combined treatment with IFNg and PMA are plotted on the left (A) and expression levels of MHCII 
induced by combined treatment with IFNg, PMA and ethanol are plotted on the right (B). The experiment was repeated 4 
times. Different treatments were compared to group 20a or 20b (see Table 1 for details on group codes). Asterisks indicate 
significant differences on post-hoc tests: *P < 0.05 by Tukey's HSD test; **P < 0.05 by Scheffe's test (see the supplementary file 
"ANOVA.xls" for original data used to perform this analysis).
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specificity for PKC isoforms is limited to the 0.1–1 na-
nomolar range. In the 10–100 nM range, staurosporine
inhibits more than 20 different kinases [25].
Data shown in Figure 6 demonstrate that staurosporine
caused about a 50% inhibition of PMA-potentiated re-
sponse in LS1034 cells at a concentration of 10 nM. Com-
plete inhibition occurred at 100 nM. A much higher
concentration of GF 109203X was required to completely
Figure 3
Ethanol potentiates PMA-rescued induction of MHCII in LS1034 colon carcinoma cells. The slope of the regres-
sion line at 102 IU/ml IFNg is significantly greater than the corresponding values at 103–104 IU/ml IFNg (1.63 vs. 0.63–0.61, P < 
0.05).
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suppress PMA-potentiated response in LS1034 cells. Phys-
iological IFNg response in SW480 colon carcinoma cells
was resistant to inhibition with 1 µM GF 109203X and
was suppressed only when staurosporine concentration
was increased to 1 µM. We conclude that the PMA effect
in LS1034 cell line is most likely mediated by a PKC
isoenzyme but other protein kinases that are sensitive to
inhibition with 1 µM GF 109203X.
Bryostatin 1 rescues IFNg inducibility of MHCII in LS1034 
colon carcinoma cells
To evaluate potential clinical implications of our findings,
we asked whether the IFNg-dependent MHCII expression
in LS1034 cells could be restored by clinically achievable
concentrations of PKC agonists. Bryostatin 1 is a potent
PKC activator that has undergone extensive clinical testing
for the treatment of hematological malignancies and solid
Figure 4
Expression levels of IFNgR1 and IFNgR2 subunits of the IFNg receptor complex do not increase in four differ-
ent tumor cell lines after PMA treatment. Cells were incubated in culture medium contaning 103 ng/ml PMA and 172 
mM ethanol for 48 hr. Live (propidium iodide negative) cells were used to measure cell surface expression of IFNg receptors. 
Fixed and permeabilized cells were used to measure total expression of IFNg receptors (both cytoplasmic and cell surface). 
Mean values of two independent experiments are plotted.
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Figure 5
Expression of the Rb protein in four tumor cell lines. Rb expression is not lost in weakly inducible LS1034 colon carci-
noma (D) and MSTO-211H mesothelioma (F). Rb expression is also preserved in the non-inducible HepG2 hepatocellular car-
cinoma (G). Panels A-C show the experimental setup for measuring Rb-specific cellular fluorescence by flow cytometry.
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tumors [27]. Animal studies show that the concentration
of Bryostatin 1 in various tissues after a single intravene-
ous injection stays in a range of 10–50 ng/g for a period of
more than 72 hr [28].
Data, plotted in Figure 7, demonstrate that 10 ng/ml Bry-
ostatin added into the culture medium containing 102–
103 IU/ml IFNg induced a 5- to 6-fold increase in levels of
MHCII expression. The potentiating effect of Bryostatin
first becomes noticeable at 1 ng/ml and then reaches a
plateau at 10–100 ng/ml. At low concentration of IFNg
Figure 6
Effect of protein kinase inhibitors on physiological and PMA potentiated responses to IFNg. Expression levels of 
MHCII induced by 1,000 IU/ml IFNg alone are indicated by triangles (▲ ). Expression levels of MHCII induced by combined 
treatment with 1,000 IU/ml IFNg, 1,000 ng/ml PMA and 172 mM ethanol are indicated by squares (■ ). IFNg and PMA were 
added after cells had been pretreated with Staurosporine and GF 109203X for 1 hr. Incubation continued for the next 24 hr in 
the constant presence of inhibitors. Physiological response to IFNg in SW480 colon carcinoma cells was abrogated by 1 µM 
Staurosporine. PMA-potentiated response to IFNg in LS1034 colon carcinoma cells was abrogated by 100 nM Staurosporine or 
by 1 µM GF 109203X. Mean values of two independent experiments are plotted.
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(102 IU/ml), the effect of Bryostatin was comparable to
that of PMA. At a higher concentration of IFNg (103 IU/
ml), however, PMA was much more effective. This may
suggest that either the two PKC activators act through
different isoforms of PKC or PMA also activates enzymes
outside the PKC family such as MAPK [18]. Whatever the
mechanism, it appears possible to restore the IFNg-de-
pendent MHCII expression in LS1034 cell line by clinical-
ly acceptable concentrations of Bryostatin 1.
Discussion
The effect of PKC activators PMA and Bryostatin 1 on IFNg
inducibility of MHCII in three resistant tumor cell lines of
different histological origin has been examined. We found
that PKC activators rescued high levels of MHCII expres-
Figure 7
MHCII inducibility can be restored in LS1034 colon carcinoma cells by a clinically tested PKC activator Bry-
ostatin 1. Cells were incubated in culture medium contaning various concentrations of IFNg, PMA or Bryostatin for 48 hr. 
Different combinations of IFNg and PMA or IFNg and Bryostatin were compared to treatment with IFNg alone (the group indi-
cated by the circle). Experiment was replicated 3 times. Mean values ± sd are plotted. Asterisks indicate the significant differ-
ences on post-hoc tests (* P < 0.05 by Tukey's HSD test). The potentiating effect of Bryostatin reached a plateau at a 
concentration of 10 ng/ml.
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sion in colon carcinoma cells and failed to do so in mes-
othelioma and hepatocellular carcinoma cells. A poor
response of tumor cells to IFNg is in agreement with pre-
vious observations that many tumors acquire such resist-
ance upon malignant transformation, possibly important
as a mechanism of tumor escape from immune
surveillance [29]. The nature of this phenomenon is com-
plex, and multiple defects that can prevent IFNg responses
in tumor lines have been described.
Most frequently, poor MHCII inducibility in response to
IFNg has been attributed to alterations in the IFNg
signalling pathway and epigenetic silencing of gene ex-
pression (reviewed in Ref [13]). The cascade of IFNg sig-
nalling events leading to transcription activation of
MHCII genes has been characterized in great detail (re-
viewed in Ref [30]). Binding of IFNg to its receptor results
in JAK-mediated phosphorylation of STAT1 on Tyrosine
701. In addition, IFNg interaction with the receptor leads
to p38MAPK-mediated phosphorylation of STAT1 on Ser-
ine 727 [17]. The phosphorylated STAT1 dimerizes and
translocates into the nucleus where it activates transcrip-
tion of several other factors including CIITA [31]. Al-
though the results of this study do not allow us to describe
the exact mechanism of PMA involvement in IFNg signal-
ling in LS1034 cell, at least two non-mutually exclusive
scenarios can be hypothesized:
1. PMA could act through the JAK-STAT signalling path-
way. It has been established that, to achieve its maximal
transcriptional activity, STAT1 must be phosphorylated
on both Tyr701 and Ser727 [32]. Phosphorylation of
STAT1 on Ser727 occurs in response to LPS, UV irradia-
tion and other agents that activate the p38MAPK pathway
[33]. As phorbol esters can also stimulate the MAPK cas-
cade through activation of PKC [34], it is tempting to
speculate that combined treatment of cells with PMA and
IFNg could increase the pool of STAT1 molecules phos-
phorylated on both Tyr701 and Ser727. This effect is most
likely mediated by PKC-delta isoenzyme as this particular
PKC isoform appears to be critical for phosphorylation of
STAT1 on Ser727 and activation of p38MAPK [16].
2. Alternatively, PMA treatment could initiate a cascade of
protein phosphorylation leading to the increase in tran-
scriptional activity of chromatin at the type IV promoter
of CIITA and/or promoter of MHCII genes. Expression of
many genes can be modified by treatment with agents act-
ing at the level of enzymes and nuclear receptors that
modify transcriptional activity of chromatin. Thus, his-
tone deacetylase inhibitors – Butyrate and Trichostatin A
– can rescue MHCII-inducibility in bladder carcinoma
cells [14] and restore constitutive MHCII expression in
plasmacytoma cells [35]. In addition to acetylation, tran-
scriptional activity of chromatin is also regulated through
phosphorylation (reviewed in Ref. [36]). It has been
shown that treatment of cells with phorbol esters leads to
accumulation of phosphorylated H3 histones [37]. There-
fore, it seems possible that in LS1034 cells PMA could en-
hance transcriptional activity of chromatin at promoters
of MHCII and/or CIITA genes. This possibility appears
particularly important since the specific lack of CIITA in-
ducibility was cited as the most common basis for lack of
IFNg-induced MHCII expression among Rb-positive hu-
man tumor lines [13,21].
Another reported mechanism of IFNg resistance in tumor
cells is associated with down-regulation of IFNg-receptors
[38]. The relevance of this mechanism to MHCII induci-
bility was recently supported by the evidence that PMA is
able to enhance IFNg-dependent MHCII expression in
THP-1 human leukemia cells through the up-regulation of
IFNg receptors [19]. In our experiments, however, the in-
cubation of LS1034 cells with PMA and ethanol did not
lead to any changes in IFNgR expression as determined by
flow cytometry (Figure 4). Therefore, it is unlikely that up-
regulated IFNgR contributed to the phenomena reported
here. It should be emphasized that we determined the ex-
pression of both IFNgR1 and IFNgR2 receptor subunits
since it has been shown that, in certain experimental sys-
tems, an IFNg resistance was due to a lack of cellular ex-
pression of IFNgR2 chain alone [39].
We also found that the effect of PMA in LS1034 cells can
be significantly augmented by co-incubation with 172
mM ethanol. In certain types of tissues, ethanol has been
shown to induce membrane translocation of PKC
isoforms through activation of phospholipase A and re-
lease of diacylglycerol [40]. This mechanism, however,
does not appear to be significant in our case as ethanol
without PMA failed to potentiate IFNg-induced MHCII ex-
pression in LS1034 cells. Alternatively, ethanol can mod-
ulate the activity of mitogen- and stress-activated kinase
cascades. It has been shown that hepatocytes exposed to
100 mM ethanol for 16 hr have a higher activity of
p38MAPK induced by EGF treatment [41]. If in our exper-
iments PMA did act through Ser727 phosphorylation of
STAT1, the potentiating effect of ethanol can possibly be
explained by its ability to stimulate the MAPK kinase
cascade.
It remains to be determined whether the restoration of
IFNg-induced MHCII expression by PMA is unique to
LS1034 cells. A potentiating effect of PMA has been re-
ported in thyroid carcinoma cells [20] but, in contrast to
LS1034 cells, normal IFNg response in those cells was
only partially lost as a result of malignant transformation.
Whether or not this phenomenon may be reproduced
with other IFNg-resistant colon carcinoma cell lines is of
particular interest, since colonic epithelium is physiologi-Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/4
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cally exposed to PKC activators that enhance cytokine sig-
nalling in enterocytes during inflammatory responses
within the intestinal mucosa [42].
It is well established that, besides the MHCII molecules,
IFNg can induce susceptible tumors to upregulate the ex-
pression of MHC class I antigens [43], tumor associated
antigens [44], costimulatory molecules [45], and heat
shock proteins [46]. In addition, IFNg may have antimet-
abolic and antiproliferative influence on certain types of
tumor cells [47]. It has also been suggested that IFNg may
cause responding tumor cells to secrete angiogenesis in-
hibitors [48]. As it is not known which of those IFNg ef-
fects are missing or restored by PMA in LS1034 cells, a
thorough evaluation of the possible clinical implications
of our in vitro findings is quite difficult. However, if clini-
cally tested PKC agonists such as Bryostatin 1 are able to
rescue the IFNg-induced MHCII expression within the tu-
mor bed, it might be appropriate to consider them for tri-
als to improve the clinical efficacy of cancer
immunotherapy.
Conclusions
In this study we showed that IFNg-inducibility of MHCII
antigens in weakly inducible LS1034 colorectal carcinoma
cell line can be rescued by concomitant incubation with
PKC agonists. Bryostatin 1 may be considered for further
investigation of IFNg-dependent MHCII induction in re-
sistant tumors in vivo.
Materials and Methods
Cell lines
Human tumor cell lines – LS1034 colorectal carcinoma
(ATCC Number: CRL-2158), SW480 colorectal adenocar-
cinoma (ATCC Number: CCL-228), MSTO-211H bipha-
sic mesothelioma (ATCC Number: CRL-2081) and
HepG2 hepatocellular carcinoma (ATCC Number: HB-
8065) – were purchased from American Type Culture Col-
lection. Cultures were routinely tested for Mycoplasma
contamination by Specialty Laboratories (Santa Monica,
CA) and were consistently negative.
Chemicals
Recombinant human Interferon γ1b, specific activity
3·107 IU/mg, was purchased from InterMune Pharma-
ceuticals. Staurosporine and GF 109203X were from Cal-
biochem. Other chemicals used were phorbol 12-
myristate 13-acetate, dimethyl sulfoxide, ethanol, propid-
ium iodide and saponin (all from Sigma). Fetal calf serum
and RPMI-1640 culture medium supplemented with 25
mM HEPES were from Irvine Scientific. Tobramycin, L-
glutamine and 0.25% porcine trypsin – 0.53 mM EDTA
were from Abbott Laboratories, BioWittaker and Gibco
correspondingly.
Antibodies
Monoclonal antibodies used in the study were: 1) mAb
against human HLA-DR,DP,DQ, FITC conjugate (anti-
MHCII-FITC), clone Tü39, mouse IgG2a; 2) mAb against
human IFNg receptor R1 chain, biotin conjugate, clone
MMHGR-1, mouse IgG1; 3) mAb against human IFNg re-
ceptor R2 chain, biotin conjugate, clone MMHGR-2,
mouse IgG1; 4) mouse IgG2a isotype control mAb, FITC
conjugate (IgG2a-FITC); 5) mouse IgG1 isotype control
mAb, biotin conjugate; 6) mAb against Rb protein, FITC
conjugate (Rb-FITC), clone G3-245, mouse IgG1; 7)
mouse IgG1 isotype control mAb, FITC conjugate (IgG1-
FITC). Streptavidin, phycoerythrin conjugate (SA-PE) and
Streptavidin, Alexa Fluor®488 conjugate (SA-Alf488) were
from eBioscience and Molecular Probes.
Cell culture
Cells were propagated in T75 flasks in RPMI-1640 medi-
um supplemented with 25 mM HEPES, 10% fetal calf se-
rum, 200 mM L-glutamine and 40 µg/ml Tobramycin.
When cells were in exponential growth phase, they were
removed from plastic by trypsinization and seeded into
the wells of 6-well trays (9 cm2/well) at a concentration of
3·105 to 5·105 cells / 4 ml / well. When cell cultures
reached 40–60% confluency (usually, on the next day),
growth medium was replaced with 2 ml of fresh medium
containing variable concentrations of IFNg. Ten minutes
later, another 2 ml of medium containing variable con-
centrations of PMA were added into the wells and the in-
cubation continued for the next 48 hr. Experiments
involving protein kinase inhibitors were performed in a
similar way, except that Staurosporine and GF 109203X
were added first, and IFNg (or PMA plus IFNg) were added
1 hr later. Staurosporine and GF 109203X were not
washed away, so the cells were incubated with IFNg+PMA
in the constant presence of inhibitors. In a first group of
experiments, stock solution of PMA was prepared at 1 mg/
ml in ethanol, and the final concentration of ethanol in
culture medium was adjusted to 10 µl/ml (172 mM). In
all subsequent experiments, stock solution of PMA was
prepared at 10 mg/ml in DMSO and the final concentra-
tion of DMSO in culture medium was adjusted to 1 µl/ml.
Immunofluorescent staining of cell surface antigens
ellular monolayers were rinsed 3 times with Ca/Mg-free
PBS and incubated for 20 min at 37°C in Hanks' balanced
salt solution containing 0.25% trypsin, 1 mM EDTA and
25 mM HEPES. Detached cells were washed twice with
staining buffer (PBS containing 10% FCS, 0.1% sodium
azide and 25 mM HEPES, pH 7.4) and stained as
described previously [49]. Briefly, cells were transferred
into the wells of round-bottom 96-well plates, the plates
were centrifuged at 200 g for 30 seconds, the supernatant
removed by shaking, and the cell pellets resuspended in
50 µl of staining buffer containing saturating concentra-Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/4
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Figure 8
Experimental conditions for measuring MHCII-specific cellular fluorescence by flow cytometry. Tumor cells 
were removed from plastic with 0.25% trypsin and 0.53 mM EDTA, washed, stained with FITC-conjugated monoclonal anti-
bodies (mAb) and analysed on a FACSCalibur™ flow cytometer. Regions R1, R2 and R3 were drawn to exclude debris (G), 
dead cells (A, B, C) and cellular aggregates (D, E, F). Panels A and D show cells stained with propidium iodide alone. Panels 
B and E show cells stained with propidium iodide and the isotype-matched control mAb (IgG2a-FITC, 1.0 µg/50 µl). Panel C 
and F show cells stained with propidium iodide and the mAb against human HLA-DR,DP,DQ (anti-MHCII-FITC, clone Tü39, 
0.25 µg/50 µl). Panel H shows frequency distributions of cells that passed R1 & R2 & R3 logical gate. M1, M2 and M3 are the 
median values of autofluorescence peak (M1 = 222), isotype control peak (M2 = 234) and HLA-DR peak (M3 = 445).
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tion of anti-MHCII-FITC. After 30-min incubation at 4°C,
cells were washed twice, resuspended in staining buffer
and kept on ice before analysis on a flow cytometer (FAC-
SCalibur™, Becton Dickinson Immunocytometry Sys-
tems). Immediately before analysis, 1 µg/ml propidium
iodide was added to exclude dead cells. Matching isotype
control mAb (IgG2a-FITC) was used at the same (0.25 µg/
well) or a higher (1.0 µg/well) concentration as the specif-
ic antibody. The lack of staining of controls demonstrated
that non-specific binding of IgG2a-FITC to PI-negative
cells was negligible in all experimental groups (Fig
8B,8E,8H). Staining for cell surface IFNg receptors was
performed similarly, except that cells were first incubated
with biotin-conjugated mAb's (specific or isotype-
matched) for 30 min, washed 2 times and then stained
with SA-Alf488. Staining of fresh and trypsin-treated
monocytes demonstrated that epitopes recognized by the
mAb's against MHCII, IFNgR1 and IFNgR2 were resistant
to 30 min digestion with 0.25% trypsin.
Immunofluorescent staining of cytoplasmic antigens
Cytoplasmic IFNgR1 and IFNgR2 receptor subunits were
detected by using a procedure described for intracellular
cytokine staining [50]. Briefly, cells were fixed in ice-cold
4% formaldehyde for 5 min, washed 2 times, permeabi-
lized in staining buffer containing 0.2% saponin for 60
min at 4°C, incubated with biotin-conjugated mAb's
(specific or isotype-matched) for 30 min, washed 2 times,
incubated with SA-PE and washed again (saponin was
present in staining buffer at all times). After the final
wash, cells were resuspended in buffer without saponin
and kept on ice until analysis. Monocytes expressing high
levels of IFNgR1 and IFNgR2 receptor subunits served as a
positive control. Expression levels of Rb protein was
measured using a procedure described elsewhere [51].
Flow cytometry
Fluorescent emission of FITC and Alexa Fluor®488 was
collected on the FL1 detector (530 ± 30 nm, log mode)
and fluorescence of PI-stained DNA was collected on the
FL3 detector (>650 nm, log mode). Incubation of tumor
cells with PMA or staurosporine dramatically increased
cell-to-cell adherence and number of cell clumps. To deal
with this problem, the FL2 detector (585 ± 42 nm, linear
mode) was used to measure area and width of electronic
pulses. PMT voltage of the FL2 detector was set high
enough to minimize the number of FL2-width events ap-
pearing in channel 1. Regions R1, R2 and R3 were drawn
to exclude debris (Fig 8G), dead cells (Fig 8A,8B,8C) and
cellular aggregates (Fig 8D,8E,8F). Acquisition was
stopped when at least 10,000 events had passed R1 & R2
& R3 logical gate (Figure 8H). List mode data files were
transferred to a Windows-based computer for off-line
analysis. Data were gated and the median values of fluo-
rescence peaks were computed by using FCSExpress soft-
ware written by David Novo http://
www.denovosoftware.com.
Data Analysis
Total fluorescence of cells stained with MHCII-FITC anti-
body can be divided into 3 sources: (1) fluorescence
caused by specific binding of MHCII-FITC, (2) fluores-
cence of MHCII-FITC bound to cells non-specifically and
(3) autofluorescence of intracellular molecules such as
NAD(P)H. An experiment performed to assess contribu-
tion of each of the three sources demonstrated that: (1)
non-specific binding of IgG2a-FITC was negligible in all
experimental groups (Fig 8H); (2) tumor cells incubated
with PMA alone did not bind anti-MHCII mAb above the
level of isotype control and (3) tumor cells incubated with
PMA (or with PMA+IFNg) demonstrated 1.2–1.4 fold in-
crease in autofluorescence. In order to correct for non-spe-
cific increase in autofluorescence, "brightness" of cells
treated with PMA alone (Table 1, column 1) was subtract-
ed from "brightness" of cells treated with PMA+IFNg
(Table 1, columns 2–4), e.g., group 05a value was sub-
tracted from values of group 11a, 17a and 23a, etc. All sta-
tistics were calculated using these corrected values that
represent distances (channel shifts) between median of
fluorescence peaks. The additional file 1 contains both
raw and corrected fluorescence values used to perform the
analysis.
Note added in proof
While the manuscript was under review, results of a clini-
cal trial had been published showing that a systemic com-
bination treatment with IFNg and GM-CSF for as long as
9-weeks failed to induce MHCII on tumor cells in 9 out of
15 hepatocellular carcinoma patients. However, those 6
patients with inducible MHCII on hepatoma cells had
better median survival as compared to MHCII negative
cases (p < 0.0001) [52].
List of abbreviations used
class II transactivator CIITA
dimethyl sulfoxide DMSO
fetal calf serum FCS
fluorescein isotiocyanate FITC
interferon-gamma IFNg
interferon-gamma receptor IFNgR
interferon-gamma receptor alpha-chain IFNgR1
interferon-gamma receptor beta-chain IFNgR2Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/4
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granulocyte-macrophage colony-stimulating factor GM-
CSF
Janus kinase JAK
major histocompatibility complex class II antigens MHCII
mitogen-activated protein kinase MAPK
monoclonal antibody mAb
phorbol 12-myristate 13-acetate PMA
propidium iodide PI
protein kinase c PKC
signal transducer and activator of transcription 1 STAT1
the retinoblastoma tumor suppressor protein Rb
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